The total number of short positions at Biodesix, Inc. saw a significant decrease during December, resulting in fewer short positions overall. Compared to the total of 347,800 shares that were available for a short sale on December 15, there were a total of 280,900 shares available for a short sale as of December 30. This represents a decrease of 19.2% from the total number of shares that were available for a short sale on December 15. Short sales account for approximately 1.1% of the total number of shares issued by the company. It is possible to derive the current short-interest ratio of 1.4 days based on an average daily trading volume of 201,100 shares. This ratio can be found in the table below.
On November 3, the most recent quarterly earnings report for Biodesix (NASDAQ: BDSX) was made public for investors to view. The company reported that its earnings per share (EPS) for the quarter came in at $0.34, which was lower than the consensus estimate of $0.02 that market analysts made. The company’s return on equity and net margin were in the red for Biodesix. The net margin was down 162.97%, and the return on equity was down 723.65%. The revenue brought in by the company for the quarter was significantly higher than the analysts’ prediction of $10.90 million, which was that the company would bring in $10.90 million. According to the projections of industry experts, Biodesix will finish the current fiscal year with earnings of -1.4 cents per share.
However, only 837 shares changed hands, a significantly lower volume than its typical daily turnover of 124,840. The price of BDSX increased by $0.14 during trading on Friday, reaching $2.37. The debt-to-equity ratio was calculated to be 1.12, the current ratio was calculated to be 0.64, and the quick ratio was also calculated to be 0.64. Over the previous twelve months, the cost of Biodesix ranged from a low of $0.95 to a high of $4.78. The stock has traded at a moving average price of $1.76 over the past 50 trading days, while its price has traded at an average of $1.71 over the past 200 trading days. The company’s price-to-earnings ratio is 1.29, and its beta value is 1.48. The company’s current value, as measured by its market capitalization, is $99.76 million.
In a published report, William Blair reaffirmed its “outperform” recommendation for Biodesix shares.